Analysis of clinical features of ovarian cancer (OC) and breast cancer (BC) among BRCA mutated (BRCA+) and sporadic (NH) double tumors

ASCO 2102 Abstract #100933 Analysis of clinical features of ovarian cancer (OC) and breast cancer (BC) among BRCA mutated (BRCA+) and sporadic (NH) doublé tumors. Maria Omelia Nicoletto, Lucia Borgate, Grazia Artioli, Alessandra Perin, Fable Zustovich, Cristina Ghiotto, Haralabos Koussis, Alessandro Cappetta, Simone Mocellin, Lara Furini, Maurizia Dalla Palma, Alfredo Èrcoli, Pietro Litta, Giovanni B. Nardelli, Vittorina Zagonel; Medicai Oncology 1, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy; Medicai Oncology 1, Istituto Oncologico Veneto (IOV), IRCCS, Padova, Italy; Department of Medicai Science, Oncology-Haematology, Mirano, Mirano-Venice, Italy; Medicai Oncology, Azienda ULSS 4 Alto Vicentino, , Thiene (VI), Italy; Medicai Oncology 1, Istituto Oncologico Veneto - IRCCS, Padua, Italy; Medicai Oncology 2, Istituto Oncologico Veneto (IOV), IRCCS, Padova, Italy; Department of Oncological and Surgical Sciences, University of Padua, Padova, Italy; Gynecology Department, Casa di Cura Abano Terme, Abano Terme, Padova, Italy; Dipartimento di Scienze Ginecologiche e della Riproduzione Umana, Università degli studi di Padova, Padova, Italy; Clinica Ginecologica e Ostetrica, Università di Padova, Padova, Italy; Medicai Oncology 1, Istituto Oncologico Veneto - IRCCS, Padova, Italy Abstract Text: Background: Women BRCA+ are at significant risk of developing both OC and BC. Doublé tumors could arise also in NH patients. Whether thè clinical outcome of doublé OC and BC is different in BRCA+ and in NH subjects is unknown. Methods: The databases of thè Istituto Oncologico Veneto (IOV), Medicai Oncology Department of Mirano (VE) and Thiene (VI) were searched to identify thè clinical and pathological features of (BC) and (OC) arisen in BRCA+ subjects as well as patients with both malignancy but tested negative/no-tested/unknown for BRCA1/2 mutation (NH). The primary endpoint was to establish if OC instead of BC needs a more intensive follow-up because it principally affects patient's prognosis. Patients were censored at last follow-up or death (any cause) for determination of overall survival (OS). OS estimates were determined using thè Kaplan-Meier method and compared by means of log-rank test. The Fisher's exact test and thè t-test were used to compare frequencies and means between groups, respectively. Results: 24/31 (77%) BRCA+ and 30/49 (61%) NH had BC as their first malignancy (p=0.15). Among NH, 20 were BRCA test negative, 20 were untested and 9 unknown. BRCA+ were younger than NH at diagnosis of first malignancy (mean age 51 vs 56y, p=0.055). Sfiaterai BC was more frequent in BRCA+ than in NH (78.6% vs 28.6% p=0.001). Stage III-IV OC at diagnosis were 74% in BRCA vs 61% in NH (p=0.34). Locally advanced (stage li-Ili) BC was significantly more frequent in BRCA+ vs NH (75% vs 42%, p=0.03). No OS difference was observed between BRCA+ and NH subjects (P=0.99). Death for progression of ovarian cancer was observed in 11/31 (35%) in BRCA+ vs 10/49 (20%) patients in NH (p=0.19). No progression of breast cancer was reported in either groups. Conclusions: OC is thè killer malignancy among patients affected by OC and BC, both in BRCA+ and in NH subjects. In patients with doublé tumors, irrespective of their pathological features, a more conserving management for BC and an intensive follow-up for OC are suggested. Title:Analysis of clinical features of ovarian cancer (OC) and breast cancer (BC) among BRCA mutated (BRCA+) and sporadic (NH) doublé tumors. https://asco.confex.com/asco/2012/sci/papers/viewonly.cgi?username=100933&pass... 02/02/2012